| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
|
| ln Vivo |
Ro60-0175 (1 mg/kg; subcutaneous injection) retained the regular responses observed in drug-treated control animals, but drug-treated animals reached their turning point earlier [1]. Ro60-0175 (0.3, Ro60-0175 (0.5 mg/kg SB242084; 1 mg/kg Ro60-0175; subcutaneous injection) versus vehicle 1 and 3 mg/kg; subcutaneous injection) in the recovery group significantly reduced the response to active levers in the recovery group response[1]. In contrast, the response was reduced, and weight loss with SB242084 prevented this effect. There were no significant main effects or interactions for responses to the inactive lever [1].
|
|---|---|
| Animal Protocol |
Animal/Disease Models: Adult male SD (SD (Sprague-Dawley)) rats (280-320 g)[1]
Doses: 1 mg/kg Route of Administration: subcutaneous injection Experimental Results: Control animals in the drug treatment group retained the regularity of responses, but drug treatment of animals reached the breakpoint earlier. Animal/Disease Models: Adult male SD (SD (Sprague-Dawley)) rat (280-320 g) [1] Doses: 0.5 mg/kg (SB242084), 1 mg/kg (Ro60-0175) Route of Administration: sc (Ro60-0175), ip (SB242084) Experimental Results: SB242084 diminished the response to cocaine and the effects were reversed. Animal/Disease Models: Adult male SD (SD (Sprague-Dawley)) rat (280-320 g) [1] Doses: 0.3, 1 and 3 mg/kg (Ro60-0175), 1 mg/kg (yohimbine) Route of Administration: subcutaneous injection (Ro60-0175), intraperitoneal (ip) injection (yohimbine) Experimental Results: Yohimbine treatment alone increased the response relative to vehicle injection and this response was dose-dependently attenuated by Ro60-0175. Animal/Disease Models: Adult male SD (SD (Sprague-Dawley)) rat (280-320 g) [1] Doses: 0.5 mg/kg (SB242084), 1 mg/kg (Ro60-0175), 1 mg/kg (yohimbine) Ad |
| References |
[1]. Fletcher PJ, et al. The 5-HT2C receptor agonist Ro60-0175 reduces cocaine self-administration and reinstatement induced by the stressor yohimbine, and contextual cues. Neuropsychopharmacology. 2008;33(6):1402-1412.
|
| Molecular Formula |
C11H12CLFN2
|
|---|---|
| Molecular Weight |
226.679
|
| Exact Mass |
226.07
|
| Elemental Analysis |
C, 58.29; H, 5.34; Cl, 15.64; F, 8.38; N, 12.36
|
| CAS # |
169675-08-5
|
| Related CAS # |
Ro60-0175 fumarate;169675-09-6
|
| Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
| SMILES |
C[C@H](N)CN1C=CC2=C1C=C(Cl)C(F)=C2
|
| InChi Key |
XJJZQXUGLLXTHO-ZETCQYMHSA-N
|
| InChi Code |
InChI=1S/C11H12ClFN2/c1-7(14)6-15-3-2-8-4-10(13)9(12)5-11(8)15/h2-5,7H,6,14H2,1H3/t7-/m0/s1
|
| Chemical Name |
(S)-1-(6-chloro-5-fluoro-1H-indol-1-yl)propan-2-amine
|
| Synonyms |
Ro60-0175; Ro-60-0175; Ro 60-0175; Ro600175; Ro-600175; Ro 600175;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~125 mg/mL (~551.44 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (9.18 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (9.18 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (9.18 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.4115 mL | 22.0575 mL | 44.1151 mL | |
| 5 mM | 0.8823 mL | 4.4115 mL | 8.8230 mL | |
| 10 mM | 0.4412 mL | 2.2058 mL | 4.4115 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
